Bg pattern

ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Icatibant Hikma 30 mg solution for injection in pre-filled syringe EFG

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Icatibant Hikma and what is it used for
  2. What you need to know before you use Icatibant Hikma
  3. How to use Icatibant Hikma
  4. Possible side effects
  5. Storing Icatibant Hikma
  6. Contents of the pack and other information

1. What is Icatibant Hikma and what is it used for

Icatibant Hikma contains the active substance icatibant.

Icatibant is used to treat acute attacks of hereditary angioedema (HAE) in adults, adolescents, and children aged 2 years and older.

In HAE, levels of a substance called bradykinin increase in the blood, leading to symptoms such as swelling, pain, nausea, and diarrhea.

Icatibant blocks the action of bradykinin and therefore reduces the progression of symptoms.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Icatibant Hikma

Do not use Icatibant Hikma

  • if you are allergic to icatibant or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor before starting treatment with this medicine:

  • If you have coronary heart disease (reduced blood flow to the heart).
  • If you have recently had a stroke.

Side effects related to icatibant are similar to the symptoms of your own disease. Consult your doctor immediately if you notice that the symptoms of the attack worsen after you have been given icatibant.

In addition:

  • You or your caregiver should learn the technique for administering subcutaneous injections (under the skin) before you self-administer or your caregiver administers icatibant to you.
  • Immediately after self-administering icatibant or after your caregiver has administered it to you while you are experiencing a laryngeal attack (obstruction of the upper airway), you should seek medical attention at a medical institution.
  • If your symptoms do not resolve after a self-administered injection of icatibant or after an injection administered by your caregiver, you should consult your doctor about administering additional injections of icatibant. In adult patients, up to 2 additional injections can be administered within 24 hours.

Children and adolescents

Icatibant is not recommended for use in children under 2 years of age or weighing less than 12 kg, as it has not been studied in these patients.

Other medicines and Icatibant Hikma

Tell your doctor if you are taking, have recently taken, or might take any other medicines.

No interactions of icatibant with other medicines are known. If you are taking any medicine that is an angiotensin-converting enzyme inhibitor (e.g., captopril, enalapril, ramipril, quinapril, lisinopril) to lower blood pressure or for any other reason, inform your doctor before using icatibant.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.

If you are breastfeeding, you should not breastfeed your child for 12 hours after the last administration of icatibant.

Driving and using machines

Do not drive or use machines if you feel tired or dizzy as a result of the HAE attack or after using icatibant.

Icatibant Hikma contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per 3 ml, which is essentially "sodium-free".

3. How to use Icatibant Hikma

Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, consult your doctor again.

If you have never been administered icatibant before, the first dose of icatibant should always be injected by medical or nursing staff. Your doctor will discharge you when they consider it safe for you to go home. After discussing with your doctor or nurse and learning the technique for subcutaneous injections (under the skin), you or your caregiver can administer icatibant if you have an HAE attack. It is essential to inject icatibant subcutaneously (under the skin) as soon as you notice an angioedema attack. Healthcare staff will teach you and your caregiver how to safely inject icatibant 30 mg/3 ml, following the instructions in the package leaflet.

When and how often should you use Icatibant Hikma?

Your doctor has determined the exact dose of icatibant and will tell you how often to use it.

Adults

  • The recommended dose of icatibant is one injection (3 ml, 30 mg) administered subcutaneously (under the skin) as soon as you notice the angioedema attack (e.g., with increased skin swelling, especially on the face and neck, or increased abdominal pain).
  • If you do not notice an improvement in symptoms after 6 hours, you should seek medical advice about administering additional injections of icatibant. In adults, up to 2 additional injections can be administered within 24 hours.
  • You should not receive more than 3 injections in a 24-hour period, and if you need more than 8 injections in a month, you should seek medical advice.

Children and adolescents from 2 to 17 years

  • The recommended dose of icatibant is an injection of 1 ml up to a maximum of 3 ml, depending on body weight, administered subcutaneously (under the skin) as soon as symptoms of an angioedema attack appear (e.g., increased skin swelling, especially on the face and neck, or increased abdominal pain).
  • Consult the section on instructions for use to see the dose you should inject.
  • If you are unsure about the dose to inject, consult your doctor, pharmacist, or nurse.
  • If your symptoms worsen or do not improve, you should seek medical advice immediately.

How should you administer Icatibant Hikma?

Icatibant is administered by subcutaneous injection (under the skin). Each syringe should only be used once.

Icatibant is injected with a short needle into the fatty tissue under the skin of the abdomen (belly). If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

The following step-by-step instructions are intended for:

  • self-administration (adults)
  • administration by a caregiver or healthcare professional for adults, adolescents, or children over 2 years (weighing at least 12 kg).

The instructions include the following main steps:

  1. General information

2a) Preparation of the syringe for children and adolescents (2-17 years) weighing 65 kg or less

2b) Preparation of the syringe and needle for injection (all patients)

  1. Preparation of the injection site
  2. Injection of the solution
  3. Disposal of injection materials

Step-by-step instructions for injection

1) General information

  • Clean the work surface (area) before starting the process.
  • Wash your hands with water and soap.
  • Remove the pre-filled syringe from the tray.
  • Unscrew and remove the cap from the end of the pre-filled syringe.
  • Leave the pre-filled syringe once the cap is unscrewed. Do not allow the exposed tip of the syringe to touch any surface.

2a) Preparation of the syringe for children and adolescents (2-17 years)

weighing 65 kg or less:

Important information for healthcare professionals and caregivers:

When the dose is less than 30 mg (3 ml), the following equipment is needed to extract the correct dose (see information below):

  1. Icatibant Hikma 30mg/3ml pre-filled syringe (with icatibant solution)
  1. Connector (adapter)
  1. 3 ml graduated syringe

Pre-filled syringe with medication showing retracted plunger and graduated scale with separate needle protector

The required injection volume in ml should be prepared in an empty 3 ml graduated syringe (see table below).

Table 1: Dosing schedule for children and adolescents

Table with medication doses according to body weight and injection volume for ranges of 12 to 65 kg

Patients weighing more than 65 kgwill use the entire contents of the pre-filled syringe (3 ml).

If you are unsure about the volume of solution to extract, consult your doctor, pharmacist, or nurse

  1. Unscrew the caps at each end of the connector.
  1. Avoid touching the ends of the connector and the tips of the syringes to prevent contamination.
  1. Screw the connector onto the pre-filled syringe.
  1. Attach the graduated syringe to the other end of the connector, making sure both connections fit securely.

Pre-filled syringe with two black plungers and seal rings, showing connection between transparent cylindrical sections

Transfer the icatibant solution to the graduated syringe:

  1. To initiate the transfer of the icatibant solution, push the plunger of the pre-filled syringe (on the left end of the image below).

Transparent pre-filled syringe with two circular plungers and measurement marks, arrows indicating direction of push

  1. If the icatibant solution does not start to transfer to the graduated syringe, gently pull the plunger of the graduated syringe until the icatibant solution starts to flow into the graduated syringe (see image below).

Transparent pre-filled syringe with dark liquid and two black rings at the ends with arrow indicating direction

  1. Continue pushing the plunger of the pre-filled syringe until the required injection volume (dose) is transferred to the graduated syringe. Refer to Table 1 for dosing information.

If there is air in the graduated syringe:

  • Turn the connected syringes so that the pre-filled syringe is on top (see image below).

Transparent syringe with black plunger and graduated marks being filled with liquid from a transparent vial

  • Push the plunger of the graduated syringe to transfer the air back to the pre-filled syringe (this step may need to be repeated several times).
  • Extract the required volume of icatibant solution.
  1. Remove the pre-filled syringe and connector from the graduated syringe.
  1. Dispose of the pre-filled syringe and connector in the sharps container or puncture-proof container.

2b) Preparation of the syringe and needle for injection: All patients (adults, adolescents, and children)

Hands holding injection device with attached needle, turning for placement

  • Remove the needle cap from the blister pack. Do not remove the needle from the cap.
  • Remove the seal from the needle cap (the needle should remain inside the cap).

Hands holding syringe and needle with arrow indicating direction of insertion into skin

  • Holding the syringe firmly, carefully connect the needle to the pre-filled syringe while the needle is still inside the cap.
  • Screw the pre-filled syringe onto the needle while it is still inside the cap. The capped needle is now attached to the syringe.
  • Holding the syringe cylinder, remove the needle from the cap by pulling the syringe. Do not pull up on the plunger.
  • The syringe is now ready for injection.
  1. Preparation of the injection site

Hand holding small liquid drop on arm skin with curved line representing body contour

  • Choose the injection site. The injection site should be a fold of the abdomen, approximately 5-10 cm (2-4 inches) below the navel, to one side or the other. The area should be at least 5 cm (2 inches) away from any scar. Do not choose an area with bruises, inflammation, or pain.
  • Clean the injection site by rubbing it with an alcohol swab and let it dry.
  1. Injection of the solution

Hand holding syringe with needle pointing upwards over gray safety device with arrow indicating direction

  • Holding the syringe in one hand between two fingers, with your thumb on the end of the plunger.
  • Check that there is no air in the syringe by pressing the plunger until the first drop appears at the tip of the needle.

Hand holding syringe injecting into thigh skin at an angle, showing needle penetrating skin surface

  • Holding the syringe with the needle pointing towards the skin at an angle of 45 to 90 degrees.
  • Holding the syringe in one hand, with the other hand gently take a fold of skin between your thumb and fingers at the previously cleaned site.
  • Holding the skin fold, bring the syringe close and quickly insert the needle into the fold.
  • Slowly press the plunger with a firm pulse until all the fluid has been injected into the skin and no liquid remains in the syringe.
  • Press slowly so that the process takes approximately 30 seconds.
  • Release the skin fold and gently remove the needle.
  1. Disposal of injection materials

Hand holding syringe disposing of needle in white sharps container

  • Dispose of the syringe, needle, and needle cap in the sharps container or puncture-proof container.
Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Almost all patients who receive icatibant notice a reaction at the injection site (such as skin irritation, inflammation, pain, itching, redness of the skin, and burning). These effects are usually mild and improve without the need for any additional treatment.

Very common (may affect more than 1 in 10 people):

Additional reactions at the injection site (feeling of pressure, bruising, decreased sensitivity and/or numbness, increased skin rash with itching and heat).

Common (may affect up to 1 in 10 people):

Malaise

Headache

Dizziness

Fever

Itching

Rash

Redness of the skin

Abnormal liver function tests

Frequency not known (cannot be estimated from the available data):

Hives (urticaria)

Tell your doctor immediately if you notice that the symptoms of the attack worsen after you have been given icatibant 30 mg/3 ml.

If you experience side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Icatibant Hikma

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after "EXP". The expiry date refers to the last day of that month.

Do not store above 30°C. Do not freeze.

Do not use this medicine if you notice that the syringe or needle packaging is damaged or if you notice visible signs of deterioration, such as if the solution is cloudy, contains floating particles, or has changed color.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container contents and additional information

Composition of Icatibant Hikma

The active ingredient is icatibant. Each pre-filled syringe contains 30 milligrams of icatibant (as icatibant acetate). The other components (excipients) are sodium chloride, glacial acetic acid, sodium hydroxide, and water for injectable preparations.

Appearance of the product and container contents

Icatibant Hikma is presented as a clear and colorless injectable solution in a 3 ml pre-filled glass syringe. The container includes a sterile subcutaneous needle.

Icatibant Hikma is available in a single-unit container with one pre-filled syringe and one needle, or in a multiple-unit container with three pre-filled syringes and three needles.

Only certain package sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Hikma Farmacêutica (Portugal) S.A.

Estrada do Rio da Mó, 8, 8A and 8B –

Fervença Terrugem SNT

2705-906

Portugal

Manufacturer

Universal Farma S.L.

Calle Dulcinea S/n

28805 Alcalá De Henares

Madrid

Spain

For further information about this medicinal product, please contact the local representative of the marketing authorization holder:

Hikma España, S.L.U.

Calle Anabel Segura nº11, Edificio A, planta 1ª, oficina 2

28108 - Alcobendas, Madrid

Spain

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Germany

Icatibant Hikma 30 mg solution for injection in a pre-filled syringe

Austria

Icatibant Hikma 30 mg solution for injection in a pre-filled syringe

Belgium

Icatibant Hikma 30 mg solution for injection in a pre-filled syringe

Spain:

Icatibanto Hikma 30 mg solution for injection in a pre-filled syringe EFG

Finland

Icatibant Universal Farma 30 mg solution for injection in a pre-filled syringe

France

Icatibant Hikma 30 mg, solution for injection in a pre-filled syringe

Hungary

Icatibant Universal Farma 30 mg solution for injection in a pre-filled syringe

Italy:

Icatibant Hikma

Netherlands:

Icatibant Hikma 30 mg solution for injection in a pre-filled syringe

Portugal:

Icatibant Hikma

Czech Republic:

Icatibant Universal Farma

Romania

Icatibant Universal Farma 30 mg solution for injection in a pre-filled syringe

Date of last revision of this leaflet:September 2024.

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es

Online doctors for ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe

Discuss questions about ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (140)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50
5.0 (29)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
Camera Book a video appointment
€60

Frequently Asked Questions

Is a prescription required for ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe?
ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe?
The active ingredient in ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe is icatibant. This information helps identify medicines with the same composition but different brand names.
Who manufactures ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe?
ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe is manufactured by Hikma Farmaceutica (Portugal) S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ICATIBANTO HIKMA 30 mg Injectable Solution in Pre-filled Syringe?
Other medicines with the same active substance (icatibant) include FIRAZYR 30 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, ICATIBANT ACCORD 30 mg Injectable Solution in Pre-filled Syringe, ICATIBANTO AGUETTANT 30 mg Injectable Solution in Pre-filled Syringe EFG. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media